

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

Pacific Blue(TM) anti-mouse CD19

RRID:AB_439718

Type: Antibody

Proper Citation

BioLegend Cat# 115523, RRID:AB_439718

Antibody Information

URL: http://antibodyregistry.org/AB_439718

Proper Citation: BioLegend Cat# 115523, RRID:AB_439718

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 6D5

Antibody ID: AB_439718

Vendor: BioLegend

Catalog Number: 115523

Alternative Catalog Numbers: 115526

Record Creation Time: 20250819T213723+0000

Record Last Update: 20250819T233349+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-mouse CD19.

No alerts have been found for Pacific Blue(TM) anti-mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. *Cell reports. Medicine*, 102532.

Zhang Z, et al. (2026) Hematopoietic stem cells activate a latent differentiation pathway to facilitate recovery after 5-fluorouracil-induced myeloablation. *Developmental cell*, 61(5), 1044.

Lei L, et al. (2026) Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation. *Cell stem cell*, 33(6), 930.

Kadam R, et al. (2026) Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1. *Cell reports*, 45(4), 117263.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. *STAR protocols*, 6(2), 103806.

Makhijani P, et al. (2025) Amyloid- β -driven Alzheimer's disease reshapes the colonic immune system in mice. *Cell reports*, 116109.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. *Cell*, 187(11), 2703.

Barclay KM, et al. (2024) An inducible genetic tool to track and manipulate specific microglial states reveals their plasticity and roles in remyelination. *Immunity*, 57(6), 1394.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Eggert J, et al. (2024) Cbl-b mitigates the responsiveness of naive CD8+ T cells that experience extensive tonic T cell receptor signaling. *Science signaling*, 17(822), eadh0439.

Zou X, et al. (2024) Hypoxia-inducible factor 2 α promotes pathogenic polarization of stem-like Th2 cells via modulation of phospholipid metabolism. *Immunity*, 57(12), 2808.

Liu B, et al. (2022) Large-scale multiplexed mosaic CRISPR perturbation in the whole organism. *Cell*, 185(16), 3008.

Georgiev GI, et al. (2022) Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo. *Cell chemical biology*, 29(5), 811.

Cautivo KM, et al. (2022) Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. *Immunity*, 55(2), 254.

Wang Z, et al. (2022) Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion. *Immunity*, 55(6), 1067.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Tang Z, et al. (2021) Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. *Cell reports*, 37(11), 110111.

Sutherland TE, et al. (2021) Ongoing Exposure to Peritoneal Dialysis Fluid Alters Resident Peritoneal Macrophage Phenotype and Activation Propensity. *Frontiers in immunology*, 12, 715209.